What were the key takeaways from IGC Pharma’s earnings call?

Did IGC Pharma beat or miss consensus estimates last quarter?

What is IGC Pharma's gross profit margin?

What were the key takeaways from IGC Pharma's earnings call?

What is the market's earnings forecast for IGC Pharma next quarter?

What factors drove the changes in IGC Pharma's revenue and profit?

What is IGC Pharma's latest dividend and current dividend yield?

What guidance did IGC Pharma's management provide for the next earnings period?

- **Key Drug Candidate Progress**: IGC 81 reduces agitation in 2 weeks vs. 10 weeks for existing treatments.
- **Clinical Trial Expansion**: 35 sites across U.S. and Canada with 50% enrollment.
- **Cost Management**: Divested non-core assets to reduce expenses.
- **AI Innovation**: MINT-AD predicts Alzheimer's risk using multimodal data.
- **2026 Focus**: Complete phase two trial and advance pipeline.


**【CEO Summary Section】**
- IGC Pharma is advancing five Alzheimer's drug candidates, with IGC 81 in phase two CALMA trial targeting agitation in Alzheimer's patients.
- IGC 81 shows interim results reducing agitation in two weeks vs. existing medications' 6-10 week timeline.
- Expanded clinical trial sites in U.S. and Canada, with 50% enrollment completion.
- Preclinical data demonstrates IGC 81 targets amyloid plaques and tau tangles.
- MINT-AD AI platform predicts Alzheimer's risk and cognitive decline.
- Strategic divestment of non-core manufacturing assets to reduce costs.
- Focus on completing phase two trial and advancing pipeline.

**【CFO Financial Commentary】**
- Sold non-core manufacturing facility to reduce $600k annual expenses.
- Secured 10% future sale contingent rights.
- Maintaining $12M credit line and selective capital raises.
- Focus on cost-efficient clinical trial execution.

**【Q&A Highlights】**
- No further interim data releases planned before final readout.
- Trial expansion to 35 sites accelerates enrollment (14 patients/month).
- Regulatory changes to hemp industry不影响 prescription drug pipeline.
- Social media recruitment drives 14 new patients/month.
- AI platform in semifinal for $1M Alzheimer's research prize.
- 2026 milestones: complete CALMA trial, expand pipeline, deploy MINT-AD.


IGC Pharma Inc (IGC) Q2 2026 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

IGC

IGC fundamentals

You can ask Aime